Promising cocktail targets tough lung cancer
NCT ID NCT05142696
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This study tests a radioactive drug called Lutathera added to standard chemotherapy and immunotherapy for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 participants will receive the treatment, and researchers will monitor side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Cancer Institute
Orlando, Florida, 32804, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Georgetown University Lombardi Cancer Center
Washington D.C., District of Columbia, 20007 2197, United States
-
Hackensack Meridian Health
Edison, New Jersey, 88837, United States
-
Novartis Investigative Site
Innsbruck, Tyrol, 6020, Austria
-
Novartis Investigative Site
Linz, Upper Austria, A 4020, Austria
-
Novartis Investigative Site
Vienna, A-1090, Austria
-
Novartis Investigative Site
Montreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Olomouc, 779 00, Czechia
-
Novartis Investigative Site
Lille, 59000, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Montpellier, 34298, France
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Beersheba, 8457108, Israel
-
Novartis Investigative Site
Haifa, 3109601, Israel
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Amersfoort, 3813, Netherlands
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
-
Novartis Investigative Site
Guildford, Surrey, GU2 7XX, United Kingdom
-
St. Louis University
St Louis, Missouri, 63104, United States
-
University Cancer and Blood Center LLC
Athens, Georgia, 30607, United States
-
University Hospitals Of Cleveland
Cleveland, Ohio, 44106, United States
-
University of Kentucky
Lexington, Kentucky, 40536, United States
-
Vanderbilt University Medical Ctr
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (lutetium Lu 177 dotatate) plus carboplatin, etoposide, and atezolizumab
What this could lead to
If successful, this could offer a new treatment option that improves survival for people with an aggressive type of lung cancer.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to everyone. The combination may cause serious side effects or not work better than current therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.